pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104.
Ormanns S, Siveke JT, Heinemann V, Haas M, Sipos B, Schlitter AM, Esposito I, Jung A, Laubender RP, Kruger S, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Märten A, Geissler M, Greten TF, Kirchner T, Boeck S.
Ormanns S, et al. Among authors: boeck s.
BMC Cancer. 2014 Aug 28;14:624. doi: 10.1186/1471-2407-14-624.
BMC Cancer. 2014.
PMID: 25164437
Free PMC article.
Clinical Trial.